Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
- Conditions
- Breast Cancer
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT00126464
- Locations
- 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- First Posted Date
- 2005-01-07
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Translational Oncology Research International
- Target Recruit Count
- 108
- Registration Number
- NCT00100854
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
- First Posted Date
- 2004-12-14
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 736
- Registration Number
- NCT00099437
- Locations
- 🇻🇪
Research Site, Caracas, Venezuela
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
- First Posted Date
- 2004-09-29
- Last Posted Date
- 2008-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 179
- Registration Number
- NCT00093002
- Locations
- 🇬🇧
Research Site, Edinburgh, United Kingdom
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
- Conditions
- Estrogen Receptor-positive Breast CancerRecurrent Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
- Interventions
- First Posted Date
- 2004-05-19
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT00082810
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 695
- Registration Number
- NCT00075764
- Locations
- 🇺🇸
Grant Medical Center Cancer Care, Columbus, Ohio, United States
🇺🇸Mount Carmel Health - West Hospital, Columbus, Ohio, United States
🇺🇸Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
- Conditions
- Metastatic Breast CancerLocally Advanced Breast Cancer
- Interventions
- First Posted Date
- 2003-07-23
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 694
- Registration Number
- NCT00065325
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
- Conditions
- Estrogen Receptor-positive Breast CancerProgesterone Receptor-positive Breast CancerStage IV Breast CancerRecurrent Breast Cancer
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 148
- Registration Number
- NCT00057941
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
ICI 182780 in Treating Women With Metastatic Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 80
- Registration Number
- NCT00012025
- Locations
- 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇺🇸CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer
- Conditions
- Breast Cancer
- Locations
- 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.